ADC Therapeutics Unlocks M&A Potential in Strategic Royalty Deal

LAUSANNE, SWITZERLAND – February 23, 2026 – ADC Therapeutics SA (NYSE: ADCT) has executed a significant strategic maneuver, amending a key financing agreement in a move that dramatically enhances its appeal as a potential acquisition target and signals deep-seated confidence in its flagship cancer therapy, ZYNLONTA.

In an announcement today, the Swiss-based pioneer in antibody drug conjugates (ADCs) revealed it has renegotiated its royalty purchase agreement with HealthCare Royalty. The revised terms drastically reduce a major financial obstacle for any potential acquirer, slashing the company's change of control payment from a formidable $750 million down to $150 million through the end of 2027, and $200 million thereafter.

The deal, described by both parties as mutually beneficial, provides ADC Therapeutics with newfound strategic breathing room. In exchange for this flexibility, HealthCare Royalty has received warrants to purchase approximately 9.8 million common shares at an exercise price of $3.81 per share. This trade-off—swapping a large, fixed payout for a smaller one plus significant equity upside—is being interpreted by the market as a powerful vote of confidence in ZYNLONTA's long-term commercial trajectory. Investors reacted positively, with the company's stock climbing over 7% in trading following the news.

Clearing the Path in a Hot M&A Market

The most immediate impact of the amended agreement is the repositioning of ADC Therapeutics within the fiercely competitive biotech M&A landscape. The previous $750 million change of control payment was widely seen as a "poison pill"—a financial deterrent so substantial it could discourage all but the most determined suitors. By lowering this hurdle by over half a billion dollars, the company becomes a much more digestible target for large pharmaceutical companies seeking to bolster their oncology pipelines.

This move comes at an opportune time. The market for ADCs is booming, with analysts projecting it to nearly triple from over $10 billion in 2023 to almost $30 billion by 2028. This rapid growth has fueled a wave of high-profile acquisitions, including Pfizer's $43 billion takeover of Seagen and AbbVie's $10.1 billion purchase of ImmunoGen. As major players face impending patent cliffs, they are actively pursuing a "string-of-pearls" strategy, acquiring smaller, innovative firms with promising assets. With its validated ADC platform and a key commercial drug, ADC Therapeutics now fits that profile more neatly.

"We are pleased by this meaningful amendment... as it enables greater strategic flexibility for our Company," said Ameet Mallik, Chief Executive Officer of ADC Therapeutics, in a statement. This flexibility is not just about a potential sale; it also provides the company with a stronger negotiating position for partnerships, collaborations, or other strategic transactions that could accelerate ZYNLONTA's growth.

A Calculated Bet on Future Blockbuster Status

While the M&A angle is compelling, the deal's structure reveals a deeper story: a high-stakes, shared bet on ZYNLONTA's journey from a niche therapy to a potential blockbuster. By accepting warrants, HealthCare Royalty is tying a significant portion of its return directly to the future success of ADC Therapeutics' stock price, which is intrinsically linked to ZYNLONTA's performance. The warrants, which represent a potential 6.7% dilution for existing shareholders, come with a lock-up period through the end of 2027, aligning HealthCare Royalty's interests with the company's medium-to-long-term growth.

This alignment is based on a shared conviction in the drug's expanding clinical profile. "This updated agreement is a result of our belief in the long-term upside of ZYNLONTA," stated Clarke Futch, Chairman and CEO of HealthCare Royalty. "The combination of existing and upcoming ZYNLONTA data... has enhanced our confidence in the Company's focused portfolio, which we believe will unlock significant value."

Currently, ZYNLONTA is approved by both the FDA and European regulators for adult patients with relapsed or refractory large B-cell lymphoma after two or more prior lines of therapy. While it has established a foothold in this heavily pre-treated population, generating $69.3 million in net revenue in 2024, the path to the company's projected peak US revenue of $600 million to $1 billion annually lies in moving into earlier stages of treatment.

The Clinical Pipeline is Key

All eyes are now on ADC Therapeutics' clinical development pipeline, which holds the key to unlocking ZYNLONTA's full potential. Two trials are of particular importance. The first is LOTIS-5, a Phase 3 confirmatory trial evaluating ZYNLONTA in combination with the standard therapy rituximab for second-line or later diffuse large B-cell lymphoma (DLBCL). With enrollment complete, topline data is expected in late 2025 and could pave the way for full FDA approval and broader use.

The second is the LOTIS-7 trial, which is exploring ZYNLONTA in combination with next-generation bispecific antibodies. Early data has been highly encouraging, showing a 94% overall response rate in one cohort. Further results are anticipated in 2025 and could establish ZYNLONTA as a cornerstone of combination therapies in various types of lymphoma.

Success in these trials would not only expand the drug's addressable market but also validate the optimism embedded in this new financing deal. The agreement's structure, with its lock-up provisions and continued royalty payments post-acquisition, suggests that both ADC Therapeutics and HealthCare Royalty are looking beyond an immediate sale and toward the value inflection points these clinical milestones represent. The deal provides the stability and flexibility needed to see these critical trials through, ensuring that whether the company is acquired or continues to grow independently, the value of its core asset is positioned for maximal realization.